Emily K Sims1, Zunaira Chaudhry2, Renecia Watkins3, Farooq Syed1, Janice Blum4, Fangqian Ouyang5, Susan M Perkins5, Raghavendra G Mirmira6, Jay Sosenko7, Linda A DiMeglio1, Carmella Evans-Molina8. 1. Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN. 2. Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN Department of Medicine, Indiana University School of Medicine, Indianapolis, IN. 3. Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN. 4. Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN. 5. Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN. 6. Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN Department of Medicine, Indiana University School of Medicine, Indianapolis, IN Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN. 7. Division of Endocrinology, University of Miami, Miami, FL. 8. Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN Department of Medicine, Indiana University School of Medicine, Indianapolis, IN Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN Richard L. Roudebush VA Medical Center, Indianapolis, IN cevansmo@iu.edu.
Abstract
OBJECTIVE: We tested whether an elevation in the serum proinsulin-to-C-peptide ratio (PI:C), a biomarker of β-cell endoplasmic reticulum (ER) dysfunction, was associated with progression to type 1 diabetes. RESEARCH DESIGN AND METHODS: Fasting total PI and C levels were measured in banked serum samples obtained from TrialNet Pathway to Prevention (PTP) participants, a cohort of autoantibody-positive relatives without diabetes of individuals with type 1 diabetes. Samples were obtained ∼12 months before diabetes onset from PTP progressors in whom diabetes developed (n = 60), and were compared with age-, sex-, and BMI-matched nonprogressors who remained normoglycemic (n = 58). PI:C ratios were calculated as molar ratios and were multiplied by 100% to obtain PI levels as a percentage of C levels. RESULTS: Although absolute PI levels did not differ between groups, PI:C ratios were significantly increased in antibody-positive subjects in whom there was progression to diabetes compared with nonprogressors (median 1.81% vs. 1.17%, P = 0.03). The difference between groups was most pronounced in subjects who were ≤10 years old, where the median progressor PI:C ratio was nearly triple that of nonprogressors; 90.0% of subjects in this age group within the upper PI:C quartile progressed to the development of diabetes. Logistic regression analysis, adjusted for age and BMI, demonstrated increased odds of progression for higher natural log PI:C ratio values (odds ratio 1.44, 95% CI 1.02, 2.05). CONCLUSIONS: These data suggest that β-cell ER dysfunction precedes type 1 diabetes onset, especially in younger children. Elevations in the serum PI:C ratio may have utility in predicting the onset of type 1 diabetes in the presymptomatic phase.
OBJECTIVE: We tested whether an elevation in the serum proinsulin-to-C-peptide ratio (PI:C), a biomarker of β-cell endoplasmic reticulum (ER) dysfunction, was associated with progression to type 1 diabetes. RESEARCH DESIGN AND METHODS: Fasting total PI and C levels were measured in banked serum samples obtained from TrialNet Pathway to Prevention (PTP) participants, a cohort of autoantibody-positive relatives without diabetes of individuals with type 1 diabetes. Samples were obtained ∼12 months before diabetes onset from PTP progressors in whom diabetes developed (n = 60), and were compared with age-, sex-, and BMI-matched nonprogressors who remained normoglycemic (n = 58). PI:C ratios were calculated as molar ratios and were multiplied by 100% to obtain PI levels as a percentage of C levels. RESULTS: Although absolute PI levels did not differ between groups, PI:C ratios were significantly increased in antibody-positive subjects in whom there was progression to diabetes compared with nonprogressors (median 1.81% vs. 1.17%, P = 0.03). The difference between groups was most pronounced in subjects who were ≤10 years old, where the median progressor PI:C ratio was nearly triple that of nonprogressors; 90.0% of subjects in this age group within the upper PI:C quartile progressed to the development of diabetes. Logistic regression analysis, adjusted for age and BMI, demonstrated increased odds of progression for higher natural log PI:C ratio values (odds ratio 1.44, 95% CI 1.02, 2.05). CONCLUSIONS: These data suggest that β-cell ER dysfunction precedes type 1 diabetes onset, especially in younger children. Elevations in the serum PI:C ratio may have utility in predicting the onset of type 1 diabetes in the presymptomatic phase.
Authors: I Truyen; P De Pauw; P N Jørgensen; C Van Schravendijk; O Ubani; K Decochez; E Vandemeulebroucke; I Weets; R Mao; D G Pipeleers; F K Gorus Journal: Diabetologia Date: 2005-10-07 Impact factor: 10.122
Authors: Anna Biason-Lauber; Marianne Böni-Schnetzler; Basil P Hubbard; Karim Bouzakri; Andrea Brunner; Claudia Cavelti-Weder; Cornelia Keller; Monika Meyer-Böni; Daniel T Meier; Caroline Brorsson; Katharina Timper; Gil Leibowitz; Andrea Patrignani; Remy Bruggmann; Gino Boily; Henryk Zulewski; Andreas Geier; Jennifer M Cermak; Peter Elliott; James L Ellis; Christoph Westphal; Urs Knobel; Jyrki J Eloranta; Julie Kerr-Conte; François Pattou; Daniel Konrad; Christian M Matter; Adriano Fontana; Gerhard Rogler; Ralph Schlapbach; Camille Regairaz; José M Carballido; Benjamin Glaser; Michael W McBurney; Flemming Pociot; David A Sinclair; Marc Y Donath Journal: Cell Metab Date: 2013-03-05 Impact factor: 27.287
Authors: Kristina M Utzschneider; Ronald L Prigeon; Mirjam V Faulenbach; Jenny Tong; Darcy B Carr; Edward J Boyko; Donna L Leonetti; Marguerite J McNeely; Wilfred Y Fujimoto; Steven E Kahn Journal: Diabetes Care Date: 2008-10-28 Impact factor: 19.112
Authors: Emily K Sims; Susan Geyer; Suzanne Bennett Johnson; Ingrid Libman; Laura M Jacobsen; David Boulware; Lisa E Rafkin; Della Matheson; Mark A Atkinson; Henry Rodriguez; Maria Spall; Helena Elding Larsson; Diane K Wherrett; Carla J Greenbaum; Jeffrey Krischer; Linda A DiMeglio Journal: Diabetes Care Date: 2019-09-26 Impact factor: 19.112
Authors: Laura M Jacobsen; Brittney N Newby; Daniel J Perry; Amanda L Posgai; Michael J Haller; Todd M Brusko Journal: Curr Diab Rep Date: 2018-08-30 Impact factor: 4.810
Authors: Emily K Sims; Carmella Evans-Molina; Sarah A Tersey; Decio L Eizirik; Raghavendra G Mirmira Journal: Diabetologia Date: 2018-08-15 Impact factor: 10.122
Authors: Isaac V Snowhite; Gloria Allende; Jay Sosenko; Ricardo L Pastori; Shari Messinger Cayetano; Alberto Pugliese Journal: Diabetologia Date: 2017-05-12 Impact factor: 10.122
Authors: Emily K Sims; Farooq Syed; Julius Nyalwidhe; Henry T Bahnson; Leena Haataja; Cate Speake; Margaret A Morris; Appakalai N Balamurugan; Raghavendra G Mirmira; Jerry Nadler; Teresa L Mastracci; Peter Arvan; Carla J Greenbaum; Carmella Evans-Molina Journal: Transl Res Date: 2019-08-09 Impact factor: 7.012
Authors: Carla J Greenbaum; Cate Speake; Jeffrey Krischer; Jane Buckner; Peter A Gottlieb; Desmond A Schatz; Kevan C Herold; Mark A Atkinson Journal: Diabetes Date: 2018-05-16 Impact factor: 9.461